Medicine
Natroba 9 mg/mL topical suspension
Natroba 9 mg/mL topical suspension is a prescription medicine containing Spinosad for topical use, marketed by Cipher Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25° C (77° F), excursions permitted to 15° to 30° C (59° to 86° F).
Key facts
- Active ingredient (INN)
- Spinosad
- Brand
- Natroba
- Strength
- 9 mg/mL
- Dosage form
- Topical suspension
- Route
- Topical
- Packs
- 1 bottle
- Marketing authorisation holder
- Cipher Pharmaceuticals
- Manufacturers
- Cipher PharmaceuticalsParaPRO
- Origin register
- US FDA, United States
- Storage
- Store at 25° C (77° F), excursions permitted to 15° to 30° C (59° to 86° F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 January 2011
- Identifiers
- RxCUI 1085816, 1085820DailyMed set ID fa90ccc8-2df0-49f7-8878-2b33e34cd272, 72cf38f4-9ef4-4b0e-b085-b02f399e2592NDC 52246-929, 84635-929Application NDA022408
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle, plastic in 1 carton / 120 mL in 1 bottle, plastic | 84635-929-04 | Cipher Pharmaceuticals | 19 January 2026 |
| 1 bottle, plastic in 1 carton / 120 mL in 1 bottle, plastic | 52246-929-04 | ParaPRO | 25 January 2011 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 18 January 2011 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Spinosad 9 mg/mL topical suspension.
Clinical summary
Spinosad is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older, among other approved uses. It is available as topical suspension. MedsAcross supplies Spinosad for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SpinosadFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Natroba prescribing information (Cipher Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Natroba 9 mg/mL topical suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.